Tokyo Tape
Sign in
← Terumo

Quarterly report · Q3

4543.TEDINET S100SSIE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥683.0bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥239.1bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥618.0bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥214.7bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥105.5bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥39.0bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥93.5bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥37.5bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥105.7bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥39.3bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥92.1bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥1.69Tat 2023-12-31Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.54Tat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥475.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.22Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.07Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.22Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.07Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥163.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥162.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥91.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥74.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥53.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥41.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥68.7bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥84.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥107.332023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥40.062023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥93.252022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥107.292023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥40.052023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥93.212022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥39.962022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio71.9%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.6%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-12-31¥172m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥2.1bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥127.8bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥13.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥407.7bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥92.0bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥147.3bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥16.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥682.8bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥121.9bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥186m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥479m
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥113.4bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥358.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥83.6bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥145.5bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.6bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥617.8bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥109.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 653
ItemContextValueUnit
Non current assets IFRSCurrentQuarterInstant1022655000000JPY
Assets IFRSPrior1YearInstant1602225000000JPY
Assets IFRSCurrentQuarterInstant1691667000000JPY
Trade and other payables cl IFRSPrior1YearInstant97736000000JPY
Trade and other payables cl IFRSCurrentQuarterInstant87301000000JPY
Bonds and borrowings cl IFRSPrior1YearInstant11223000000JPY
Bonds and borrowings cl IFRSCurrentQuarterInstant151245000000JPY
Other financial liabilities cl IFRSPrior1YearInstant7597000000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant7662000000JPY
Income taxes payable cl IFRSPrior1YearInstant23563000000JPY
Income taxes payable cl IFRSCurrentQuarterInstant19916000000JPY
Provisions cl IFRSPrior1YearInstant329000000JPY
Provisions cl IFRSCurrentQuarterInstant212000000JPY
Other current liabilities cl IFRSPrior1YearInstant77551000000JPY
Other current liabilities cl IFRSCurrentQuarterInstant84903000000JPY
Total current liabilities IFRSPrior1YearInstant218001000000JPY
Total current liabilities IFRSCurrentQuarterInstant351242000000JPY
Bonds and borrowings ncl IFRSPrior1YearInstant220714000000JPY
Bonds and borrowings ncl IFRSCurrentQuarterInstant74976000000JPY
Other financial liabilities ncl IFRSPrior1YearInstant29639000000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant30499000000JPY
Deferred tax liabilities IFRSPrior1YearInstant8870000000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant3393000000JPY
Retirement benefit liability ncl IFRSPrior1YearInstant4703000000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant4923000000JPY
Provisions ncl IFRSPrior1YearInstant127000000JPY
Provisions ncl IFRSCurrentQuarterInstant104000000JPY
Other non current liabilities ncl IFRSPrior1YearInstant9106000000JPY
Other non current liabilities ncl IFRSCurrentQuarterInstant10516000000JPY
Non current labilities IFRSPrior1YearInstant273161000000JPY
Non current labilities IFRSCurrentQuarterInstant124413000000JPY
Liabilities IFRSPrior1YearInstant491162000000JPY
Liabilities IFRSCurrentQuarterInstant475656000000JPY
Share capital IFRSPrior1YearInstant38716000000JPY
Share capital IFRSCurrentQuarterInstant38716000000JPY
Capital surplus IFRSPrior1YearInstant51759000000JPY
Capital surplus IFRSCurrentQuarterInstant51690000000JPY
Treasury shares IFRSPrior1YearInstant-11539000000JPY
Treasury shares IFRSCurrentQuarterInstant-19076000000JPY
Retained earnings IFRSPrior1YearInstant874272000000JPY
Retained earnings IFRSCurrentQuarterInstant922094000000JPY
Other components of equity IFRSPrior1YearInstant157855000000JPY
Other components of equity IFRSCurrentQuarterInstant222586000000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant1111063000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant1216011000000JPY
Equity IFRSPrior1YearInstant1111063000000JPY
Equity IFRSCurrentQuarterInstant1216011000000JPY
Liabilities and equity IFRSPrior1YearInstant1602225000000JPY
Liabilities and equity IFRSCurrentQuarterInstant1691667000000JPY
Revenue IFRSPrior1YTDDuration617993000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass